Journal
GENES
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/genes11080837
Keywords
Duchenne muscular dystrophy; pathogenesis; dystrophin restoration; gene therapy; cell transplantation
Categories
Funding
- Zhejiang Provincial Natural Science Foundation [LZ19H160001]
- Fundamental Research Funds for the Central Universities [2019QN30006]
Ask authors/readers for more resources
Neuromuscular disorders encompass a heterogeneous group of conditions that impair the function of muscles, motor neurons, peripheral nerves, and neuromuscular junctions. Being the most common and most severe type of muscular dystrophy, Duchenne muscular dystrophy (DMD), is caused by mutations in the X-linkeddystrophingene. Loss of dystrophin protein leads to recurrent myofiber damage, chronic inflammation, progressive fibrosis, and dysfunction of muscle stem cells. Over the last few years, there has been considerable development of diagnosis and therapeutics for DMD, but current treatments do not cure the disease. Here, we review the current status of DMD pathogenesis and therapy, focusing on mutational spectrum, diagnosis tools, clinical trials, and therapeutic approaches including dystrophin restoration, gene therapy, and myogenic cell transplantation. Furthermore, we present the clinical potential of advanced strategies combining gene editing, cell-based therapy with tissue engineering for the treatment of muscular dystrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available